CA1109484A - 2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques - Google Patents

2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques

Info

Publication number: CA1109484A
Authority: CA; Canada
Prior art keywords: mol; intermediates; acid; compounds; formula
Prior art date: 1978-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA359,745A

Other languages

English (en)

Inventor

Sven O. Ogren

Gosta L. Florvall

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Astra Lakemedel AB

Original Assignee

Astra Lakemedel AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-03-23

Filing date

1980-09-04

Publication date

1981-09-22

1978-03-23 Priority claimed from SE7803411A external-priority patent/SE411118B/sv

1980-09-04 Application filed by Astra Lakemedel AB filed Critical Astra Lakemedel AB

1980-09-04 Priority to CA359,745A priority Critical patent/CA1109484A/fr

1981-09-22 Application granted granted Critical

1981-09-22 Publication of CA1109484A publication Critical patent/CA1109484A/fr

Status Expired legal-status Critical Current

Links

239000000543 intermediate Substances 0.000 title claims abstract description 15
238000000034 method Methods 0.000 title claims description 12
208000028017 Psychotic disease Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 41
238000002360 preparation method Methods 0.000 claims abstract description 21
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims description 9
230000002140 halogenating effect Effects 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
230000000561 anti-psychotic effect Effects 0.000 abstract description 11
229940054066 benzamide antipsychotics Drugs 0.000 abstract 1
239000000243 solution Substances 0.000 description 35
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 34
239000000203 mixture Substances 0.000 description 28
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 23
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
239000013543 active substance Substances 0.000 description 17
229960003638 dopamine Drugs 0.000 description 16
238000003756 stirring Methods 0.000 description 16
239000002904 solvent Substances 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
239000002775 capsule Substances 0.000 description 11
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 10
206010042008 Stereotypy Diseases 0.000 description 10
229960001701 chloroform Drugs 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
229960004940 sulpiride Drugs 0.000 description 10
239000003826 tablet Substances 0.000 description 10
MBIZFBDREVRUHY-UHFFFAOYSA-N 2,6-Dimethoxybenzoic acid Chemical compound COC1=CC=CC(OC)=C1C(O)=O MBIZFBDREVRUHY-UHFFFAOYSA-N 0.000 description 9
239000001828 Gelatine Substances 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229960004046 apomorphine Drugs 0.000 description 9
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 9
229920000159 gelatin Polymers 0.000 description 9
235000019322 gelatine Nutrition 0.000 description 9
208000013403 hyperactivity Diseases 0.000 description 9
229940032007 methylethyl ketone Drugs 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
UNRBEYYLYRXYCG-UHFFFAOYSA-N (1-ethylpyrrolidin-2-yl)methanamine Chemical compound CCN1CCCC1CN UNRBEYYLYRXYCG-UHFFFAOYSA-N 0.000 description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
125000000896 monocarboxylic acid group Chemical group 0.000 description 6
CUQANLQRQJHIQE-UHFFFAOYSA-N 3-bromo-2,6-dimethoxybenzoic acid Chemical compound COC1=CC=C(Br)C(OC)=C1C(O)=O CUQANLQRQJHIQE-UHFFFAOYSA-N 0.000 description 5
CLZTVXIMOQUOEI-UHFFFAOYSA-N 3-chloro-2,6-dimethoxybenzoic acid Chemical compound COC1=CC=C(Cl)C(OC)=C1C(O)=O CLZTVXIMOQUOEI-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000000164 antipsychotic agent Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000003208 petroleum Substances 0.000 description 5
BOHSCHORFQOYMV-UHFFFAOYSA-N 3,5-dibromo-2,6-dimethoxybenzoic acid Chemical compound COC1=C(Br)C=C(Br)C(OC)=C1C(O)=O BOHSCHORFQOYMV-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
239000002026 chloroform extract Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012458 free base Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229940057948 magnesium stearate Drugs 0.000 description 4
229920001592 potato starch Polymers 0.000 description 4
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
125000006360 carbonyl amino methylene group Chemical group [H]N(C([*:1])=O)C([H])([H])[*:2] 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
OYJXTOVLKZDGFK-UHFFFAOYSA-N ethanol;2-propan-2-yloxypropane Chemical compound CCO.CC(C)OC(C)C OYJXTOVLKZDGFK-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
JPIAALCEQSLBKF-UHFFFAOYSA-N 3,5-dichloro-2,6-dimethoxybenzoic acid Chemical compound COC1=C(Cl)C=C(Cl)C(OC)=C1C(O)=O JPIAALCEQSLBKF-UHFFFAOYSA-N 0.000 description 2
WCPXLMIPGMFZMY-UHFFFAOYSA-N 3-bromo-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide;hydrochloride Chemical compound [Cl-].CC[NH+]1CCCC1CNC(=O)C1=C(OC)C=CC(Br)=C1OC WCPXLMIPGMFZMY-UHFFFAOYSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001994 activation Methods 0.000 description 2
-1 alkyl carbonic acid Chemical compound 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000005457 ice water Substances 0.000 description 2
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical class C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
JCBGKPTVKBFSNZ-UHFFFAOYSA-N 3,5-dibromo-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCCC1CNC(=O)C1=C(OC)C(Br)=CC(Br)=C1OC JCBGKPTVKBFSNZ-UHFFFAOYSA-N 0.000 description 1
HRXLYQNSAFLNEJ-UHFFFAOYSA-N 3,5-dibromo-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide;hydrochloride Chemical compound [Cl-].CC[NH+]1CCCC1CNC(=O)C1=C(OC)C(Br)=CC(Br)=C1OC HRXLYQNSAFLNEJ-UHFFFAOYSA-N 0.000 description 1
JGQKBQNMKHVABS-UHFFFAOYSA-N 3,5-dichloro-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCCC1CNC(=O)C1=C(OC)C(Cl)=CC(Cl)=C1OC JGQKBQNMKHVABS-UHFFFAOYSA-N 0.000 description 1
MWGNFOKKFFBHLD-UHFFFAOYSA-N 3-bromo-5-chloro-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCCC1CNC(=O)C1=C(OC)C(Cl)=CC(Br)=C1OC MWGNFOKKFFBHLD-UHFFFAOYSA-N 0.000 description 1
GUJRSXAPGDDABA-UHFFFAOYSA-N 3-bromo-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCCC1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-UHFFFAOYSA-N 0.000 description 1
PKSWACCSAIQAEJ-UHFFFAOYSA-N 3-chloro-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide;hydrochloride Chemical compound Cl.CCN1CCCC1CNC(=O)C1=C(OC)C=CC(Cl)=C1OC PKSWACCSAIQAEJ-UHFFFAOYSA-N 0.000 description 1
FXQBDTOYQSXFQF-UHFFFAOYSA-N 3-morpholin-4-yl-n-[(4-propan-2-ylphenyl)methyl]propan-1-amine Chemical compound C1=CC(C(C)C)=CC=C1CNCCCN1CCOCC1 FXQBDTOYQSXFQF-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
244000165918 Eucalyptus papuana Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920005439 Perspex® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
229940040526 anhydrous sodium acetate Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003354 anti-apomorphinic effect Effects 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
229960003990 apomorphine hydrochloride Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
229940045024 blockade Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940106135 cellulose Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000001009 nucleus accumben Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
229960005196 titanium dioxide Drugs 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA359,745A 1978-03-23 1980-09-04 2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques Expired CA1109484A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA359,745A CA1109484A (fr)	1978-03-23	1980-09-04	2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE7803411A SE411118B (sv)	1978-03-23	1978-03-23	Ett forfarande for framstellning av 2,6-dialkoxibensamider med terapentiska egenskaper
SE7803411-3		1978-03-23
CA322,555A CA1101873A (fr)	1978-03-23	1979-03-01	Traduction non-disponible
CA359,745A CA1109484A (fr)	1978-03-23	1980-09-04	2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques

Publications (1)

Publication Number	Publication Date
CA1109484A true CA1109484A (fr)	1981-09-22

Family

ID=27166113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA359,745A Expired CA1109484A (fr)	1978-03-23	1980-09-04	2,6-dialkoxybenzamides, leurs intermediaires, substances pharmaceutiques qui en contiennent et emploi pour le traitement des desiquilibres psychotiques

Country Status (1)

Country	Link
CA (1)	CA1109484A (fr)

1980
- 1980-09-04 CA CA359,745A patent/CA1109484A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1998-09-22	MKEX	Expiry

Publication	Publication Date	Title
US4289781A (en)	1981-09-15	Anti-psychotic phthalimidine derivatives
US5245080A (en)	1993-09-14	(+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use
US4232037A (en)	1980-11-04	2,6-Dialkoxybenzamides, intermediates, pharamaceutical compositions and methods for treatment of psychotic disorders
EP0507863A1 (fr)	1992-10-14	Ligands de recepteur sigma et leur emploi
GB2087883A (en)	1982-06-03	Improvements in or relating to 3--aryloxy-3-phenylpropylamines
US4789683A (en)	1988-12-06	Benzamido-derivatives
EP0734379B1 (fr)	2001-03-07	Derives de 2-arylalkenyl-azacycloalkanes ligands aux recepteurs sigma, leur procede de preparation et leur application en therapeutique
DE3590241T (de)	1986-06-26	Neues Arzneimittel und dessen Herstellung
EP0117384B1 (fr)	1988-12-28	Dérivés de N-(1-éthyl-2-pyrrolidinylméthyl)-benzamide, procédé et produits intermédiaires pour leur préparation, et compositions pharmaceutiques les contenant
GB2176785A (en)	1987-01-07	Annellated benzamide derivatives
EP0207913B1 (fr)	1990-10-31	Catécholamides, leur procédé de préparation, intermédiaires et médicaments les contenant
AU614851B2 (en)	1991-09-12	(+) 1-((3,4,5-trimethoxy)-benzyloxymethyl)-1-phenyl-n,n- dimethyl-n-propylamine, its process of preparation and its therapeutic use
EP0820434B1 (fr)	2000-08-09	Derives de la phenoxyethylamine possedant une haute affinite pour le recepteur 5-ht 1a, leur procede de preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
US5214057A (en)	1993-05-25	N-substituted azaheterocyclic carboxylic acids
CS266312B2 (cs)	1989-12-13	Způsob výroby benzamidových derivátů
JPH07103097B2 (ja)	1995-11-08	オキシサリチルアミド誘導体
NO863924L (no)	1982-09-13	Mellomprodukter for bruk ved fremstilling av terapeutisk virksomme benzamidderivater.